The new ACAM2000™ vaccine and other therapies to control orthopoxvirus outbreaks and bioterror attacks

References

• Branda JA, Ruoff K. Bioterrorism. Clinical recognition and primary management. Am. J. Clin. Pathol.117(Suppl.), S116–S123 (2002).
   Google Scholar
• Parker S, Nuara A, Buller RM, Schultz DA. Human monkeypox: an emerging zoonotic disease. Future Microbiol.2, 17–34 (2007).
   PubMed Web of Science ®Google Scholar
• Henderson DA, Borio LL, Lane JM. Smallpox and vaccinia. In: Vaccines. Plotkin SA, Orenstein WA (Eds). Elsevier Inc., PA, USA, 123–153 (2004).
   Google Scholar
• Package insert. Acambis, Inc. ACAM2000 Smallpox (Vaccinia) Vaccine, Live (2008).
   Google Scholar
• Murphy FA, Osburn BI. Adventitious agents and smallpox vaccine in strategic national stockpile. Emerg. Infect. Dis.11(7), 1086–1089 (2005).
   PubMed Web of Science ®Google Scholar
• Osborne JD, Da Silva M, Frace AM et al. Genomic differences of vaccinia virus clones from Dryvax smallpox vaccine: the Dryvax-like ACAM2000 and the mouse neurovirulent Clone-3. Vaccine25(52), 8807–8832 (2007).
   PubMed Web of Science ®Google Scholar
• Kutinova L, Ludvikova V, Simonova V et al. Search for optimal parent for recombinant vaccinia virus vaccines. Study of three vaccinia virus vaccinal strains and several virus lines derived from them. Vaccine13(5), 487–493 (1995).
   PubMed Web of Science ®Google Scholar
• Weltzin R, Liu J, Pugachev KV et al. Clonal vaccinia virus grown in cell culture as a new smallpox vaccine. Nat. Med.9(9), 1125–1130 (2003).
   PubMed Web of Science ®Google Scholar
• Marennikova SS, Chimishkyan KL, Maltseva NN, Shelukhina EM, Fedorov VV. Proceedings of: The Symposium on Smallpox. Yugoslavia Academy of Sciences and Arts. Zagreb, Yugoslavia, 2–3 September 1969.
   Google Scholar
• Marennikova SS. International Symposium on Smallpox Vaccine. Bilthoven, The Netherlands, 11–13 October 1972. Karger, Basel (1973).
   Google Scholar
• Acambis, Inc. Investigator’s brochure for ACAM2000 smallpox vaccine. Cambridge, MA, USA (2002).
   Google Scholar
• Monath TP, Caldwell JR, Mundt W et al. ACAM2000 clonal vero cell culture vaccinia virus (New York City Board of Health strain) – a second-generation smallpox vaccine for biological defense. Int. J. Infect. Dis.8(Suppl. 2), S31–S44 (2004).
   PubMed Web of Science ®Google Scholar
• Greenberg RN, Kennedy JS. ACAM2000: a newly licensed cell culture-based live vaccinia smallpox vaccine. Expert Opin. Investig. Drugs17(4), 555–564 (2008).
   PubMed Web of Science ®Google Scholar
• Acambis, Inc. ACAM2000 prescribing information (2009).
   Google Scholar
• Acambis, Inc. ACAM2000 smallpox vaccine: Vaccines and Related Biological Products Advisory Committee (VRBPAC). FDA, CBER (2007).
   Google Scholar
• Marriott KA, Parkinson CV, Morefield SI, Davenport R, Nichols R, Monath TP. Clonal vaccinia virus grown in cell culture fully protects monkeys from lethal monkeypox challenge. Vaccine26(4), 581–588 (2008).
   PubMed Web of Science ®Google Scholar
• Frey SE, Newman FK, Kennedy JS et al. Comparison of the safety and immunogenicity of ACAM1000, ACAM2000 and Dryvax in healthy vaccinia-naive adults. Vaccine27(10), 1637–1644 (2009).
   PubMed Web of Science ®Google Scholar
• Downie AW, McCarthy K. The antibody response in man following infection with viruses of the pox group. III. Antibody response in smallpox. J. Hyg. (Lond.)56(4), 479–487 (1958).
   PubMedGoogle Scholar
• Downie AW, Saint VL, Goldstein L, Rao AR, Kempe CH. Antibody response in non-haemorrhagic smallpox patients. J. Hyg. (Lond.)67(4), 609–618 (1969).
   PubMedGoogle Scholar
• Mack TM, Noble J Jr, Thomas DB. A prospective study of serum antibody and protection against smallpox. Am. J. Trop. Med. Hyg.21(2), 214–218 (1972).
   PubMed Web of Science ®Google Scholar
• Sarkar JK, Mitra AC, Mukherjee MK. The minimum protective level of antibodies in smallpox. Bull. World Health Organ.52(3), 307–311 (1975).
   PubMed Web of Science ®Google Scholar
• Artenstein AW, Johnson C, Marbury TC et al. A novel, cell culture-derived smallpox vaccine in vaccinia-naive adults. Vaccine23(25), 3301–3309 (2005).
   PubMed Web of Science ®Google Scholar
• Couch RB, Winokur P, Edwards KM et al. Reducing the dose of smallpox vaccine reduces vaccine-associated morbidity without reducing vaccination success rates or immune responses. J. Infect. Dis.195(6), 826–832 (2007).
   PubMed Web of Science ®Google Scholar
• Rosenthal S, Merchlinsky M, Chowdhury M. VRBPAC background document: ACAM2000 (live vaccinia virus smallpox vaccine). Vaccines and Related Biological Products Advisory Committee Meeting, 17 May 2007 (2008).
   Google Scholar
• Galasso GJ, Mattheis MJ, Cherry JD et al. Clinical and serologic study of four smallpox vaccines comparing variations of dose and route of administration. Summary. J. Infect. Dis.135(1), 183–186 (1977).
   PubMed Web of Science ®Google Scholar
• Polak MF, Beunders BJ, Van Der Werff AR, Sanders EW, Van Klaveren J, Brans LM. A comparative study of clinical reaction observed after application of several smallpox vaccines in primary vaccination of young adults. Bull. World Health Organ.29, 311–322 (1963).
   PubMed Web of Science ®Google Scholar
• Lane JM, Ruben FL, Neff JM, Millar JD. Complications of smallpox vaccination, 1968. N. Engl. J. Med.281(22), 1201–1208 (1969).
   PubMed Web of Science ®Google Scholar
• Lane JM, Millar JD. Risks of smallpox vaccination complications in the United States. Am. J. Epidemiol.93(4), 238–240 (1971).
   PubMed Web of Science ®Google Scholar
• Lane JM, Ruben FL, Neff JM, Millar JD. Complications of smallpox vaccination, 1968: results of ten statewide surveys. J. Infect. Dis.122(4), 303–309 (1970).
   PubMed Web of Science ®Google Scholar
• Frey SE, Newman FK, Kennedy JS et al. Clinical and immunologic responses to multiple doses of IMVAMUNE (modified vaccinia Ankara) followed by Dryvax challenge. Vaccine25(51), 8562–8573 (2007).
   PubMed Web of Science ®Google Scholar
• Parrino J, McCurdy LH, Larkin BD et al. Safety, immunogenicity and efficacy of modified vaccinia Ankara (MVA) against Dryvax challenge in vaccinia-naive and vaccinia-immune individuals. Vaccine25(8), 1513–1525 (2007).
   PubMed Web of Science ®Google Scholar
• Grabenstein JD, Winkenwerder W Jr. US military smallpox vaccination program experience. JAMA289(24), 3278–3282 (2003).
   PubMed Web of Science ®Google Scholar
• Poland GA, Grabenstein JD, Neff JM. The US smallpox vaccination program: a review of a large modern era smallpox vaccination implementation program. Vaccine23(17–18), 2078–2081 (2005).
   PubMed Web of Science ®Google Scholar
• Arness MK, Eckart RE, Love SS et al. Myopericarditis following smallpox vaccination. Am. J. Epidemiol.160(7), 642–651 (2004).
   PubMed Web of Science ®Google Scholar
• Eckart RE, Shry EA, Jones SO, Atwood JE, Grabenstein JD. Comparison of clinical presentation of acute myocarditis following smallpox vaccination to acute coronary syndromes in patients <40 years of age. Am. J. Cardiol.95(10), 1252–1255 (2005).
   PubMed Web of Science ®Google Scholar
• Kenner J, Cameron F, Empig C, Jobes DV, Gurwith M. LC16m8: an attenuated smallpox vaccine. Vaccine24(47–48), 7009–7022 (2006).
   PubMed Web of Science ®Google Scholar
• Hirayama M. Smallpox vaccination in Japan. In: International Medical Foundation of Japan. Fukumi H (Ed.). Saunders, Tokyo, Japan, 113–124 (1975).
   Google Scholar
• Wiser I, Balicer RD, Cohen D. An update on smallpox vaccine candidates and their role in bioterrorism related vaccination strategies. Vaccine25(6), 976–984 (2007).
   PubMed Web of Science ®Google Scholar
• Kidokoro M, Tashiro M, Shida H. Genetically stable and fully effective smallpox vaccine strain constructed from highly attenuated vaccinia LC16m8. Proc. Natl Acad. Sci. USA102(11), 4152–4157 (2005).
   PubMed Web of Science ®Google Scholar
• Saito T, Fujii T, Kanatani Y et al. Clinical and immunological response to attenuated tissue-cultured smallpox vaccine LC16m8. JAMA301(10), 1025–1033 (2009).
   PubMed Web of Science ®Google Scholar
• Coulibaly S, Bruhl P, Mayrhofer J, Schmid K, Gerencer M, Falkner FG. The nonreplicating smallpox candidate vaccines defective vaccinia Lister (dVV-L) and modified vaccinia Ankara (MVA) elicit robust long-term protection. Virology341(1), 91–101 (2005).
   PubMed Web of Science ®Google Scholar
• Empig C, Higgins K, Edghill-Smith Y, Silvera P. Attenuated smallpox vaccine LC16m8 protects cynomolgus monkeys from Lethal IV monkeypox-zaire challenge, Presented at: ASM-Biodefense Meeting. Washington, DC, USA, 17 February 2006.
   Google Scholar
• Saijo M, Ami Y, Suzaki Y et al. LC16m8, a highly attenuated vaccinia virus vaccine lacking expression of the membrane protein B5R, protects monkeys from monkeypox. J. Virol.80(11), 5179–5188 (2006).
   PubMed Web of Science ®Google Scholar
• Kenner JK, Gurwith M, Luck A et al. Safety and immunogenicity of attenuated smallpox vaccine, LC16m8: results from a Phase 2 study [poster 206E]. In: Proceedings of the 4th Annual American Society for Microbiology Biodefense Research Meeting. Washington, DC, USA, 17 February 2006.
   Google Scholar
• Sutter G, Moss B. Nonreplicating vaccinia vector efficiently expresses recombinant genes. Proc. Natl Acad. Sci. USA89(22), 10847–10851 (1992).
   PubMed Web of Science ®Google Scholar
• Meyer H, Sutter G, Mayr A. Mapping of deletions in the genome of the highly attenuated vaccinia virus MVA and their influence on virulence. J. Gen. Virol.72(Pt 5), 1031–1038 (1991).
   PubMed Web of Science ®Google Scholar
• Vollmar J, Arndtz N, Eckl KM et al. Safety and immunogenicity of IMVAMUNE, a promising candidate as a third generation smallpox vaccine. Vaccine24(12), 2065–2070 (2006).
   PubMed Web of Science ®Google Scholar
• Earl PL, Americo JL, Wyatt LS et al. Rapid protection in a monkeypox model by a single injection of a replication-deficient vaccinia virus. Proc. Natl Acad. Sci. USA105(31), 10889–10894 (2008).
   PubMed Web of Science ®Google Scholar
• Meseda CA, Garcia AD, Kumar A et al. Enhanced immunogenicity and protective effect conferred by vaccination with combinations of modified vaccinia virus Ankara and licensed smallpox vaccine Dryvax in a mouse model. Virology339(2), 164–175 (2005).
   PubMed Web of Science ®Google Scholar
• Ferrier-Rembert A, Drillien R, Tournier JN, Garin D, Crance JM. Short- and long-term immunogenicity and protection induced by non-replicating smallpox vaccine candidates in mice and comparison with the traditional 1st generation vaccine. Vaccine26(14), 1794–1804 (2008).
   PubMed Web of Science ®Google Scholar
• Staib C, Suezer Y, Kisling S, Kalinke U, Sutter G. Short-term, but not post-exposure, protection against lethal orthopoxvirus challenge after immunization with modified vaccinia virus Ankara. J. Gen. Virol.87(Pt 10), 2917–2921 (2006).
   PubMed Web of Science ®Google Scholar
• Wyatt LS, Earl PL, Eller LA, Moss B. Highly attenuated smallpox vaccine protects mice with and without immune deficiencies against pathogenic vaccinia virus challenge. Proc. Natl Acad. Sci. USA101(13), 4590–4595 (2004).
   PubMed Web of Science ®Google Scholar
• Samuelsson C, Hausmann J, Lauterbach H et al. Survival of lethal poxvirus infection in mice depends on TLR9, and therapeutic vaccination provides protection. J. Clin. Invest.118(5), 1776–1784 (2008).
   PubMed Web of Science ®Google Scholar
• Paran N, Yasemin S, Lustig S et al. Post-exposure immunization with vaccinia virus MVA or conventional Lister vaccine provides solid protection in murine model for human smallpox. J. Infect. Dis.199(1), 39–48 (2009).
   PubMed Web of Science ®Google Scholar
• Pharmaceutical Technology. Third generation smallpox vaccine (2008).
   Google Scholar
• Fogg C, Lustig S, Whitbeck JC, Eisenberg RJ, Cohen GH, Moss B. Protective immunity to vaccinia virus induced by vaccination with multiple recombinant outer membrane proteins of intracellular and extracellular virions. J. Virol.78(19), 10230–10237 (2004).
   PubMed Web of Science ®Google Scholar
• Galmiche MC, Goenaga J, Wittek R, Rindisbacher L. Neutralizing and protective antibodies directed against vaccinia virus envelope antigens. Virology254(1), 71–80 (1999).
   PubMed Web of Science ®Google Scholar
• Lai CF, Gong SC, Esteban M. The purified 14-kilodalton envelope protein of vaccinia virus produced in Escherichia coli induces virus immunity in animals. J. Virol.65(10), 5631–5635 (1991).
   PubMed Web of Science ®Google Scholar
• Demkowicz WE, Maa JS, Esteban M. Identification and characterization of vaccinia virus genes encoding proteins that are highly antigenic in animals and are immunodominant in vaccinated humans. J. Virol.66(1), 386–398 (1992).
   PubMed Web of Science ®Google Scholar
• Davies DH, McCausland MM, Valdez C et al. Vaccinia virus H3L envelope protein is a major target of neutralizing antibodies in humans and elicits protection against lethal challenge in mice. J. Virol.79(18), 11724–11733 (2005).
   PubMed Web of Science ®Google Scholar
• Bell E, Shamim M, Whitbeck JC, Sfyroera G, Lambris JD, Isaacs SN. Antibodies against the extracellular enveloped virus B5R protein are mainly responsible for the EEV neutralizing capacity of vaccinia immune globulin. Virology325(2), 425–431 (2004).
   PubMed Web of Science ®Google Scholar
• Lawrence SJ, Lottenbach KR, Newman FK et al. Antibody responses to vaccinia membrane proteins after smallpox vaccination. J. Infect. Dis.196(2), 220–229 (2007).
   PubMed Web of Science ®Google Scholar
• Otero M, Calarota SA, Dai A, De Groot AS, Boyer JD, Weiner DB. Efficacy of novel plasmid DNA encoding vaccinia antigens in improving current smallpox vaccination strategy. Vaccine24(21), 4461–4470 (2006).
   PubMed Web of Science ®Google Scholar
• Pulford DJ, Gates A, Bridge SH, Robinson JH, Ulaeto D. Differential efficacy of vaccinia virus envelope proteins administered by DNA immunisation in protection of BALB/c mice from a lethal intranasal poxvirus challenge. Vaccine22(25–26), 3358–3366 (2004).
   PubMed Web of Science ®Google Scholar
• Hooper JW, Custer DM, Thompson E. Four-gene-combination DNA vaccine protects mice against a lethal vaccinia virus challenge and elicits appropriate antibody responses in nonhuman primates. Virology306(1), 181–195 (2003).
   PubMed Web of Science ®Google Scholar
• Hooper JW, Golden JW, Ferro AM, King AD. Smallpox DNA vaccine delivered by novel skin electroporation device protects mice against intranasal poxvirus challenge. Vaccine25(10), 1814–1823 (2007).
   PubMed Web of Science ®Google Scholar
• Hooper JW, Thompson E, Wilhelmsen C et al. Smallpox DNA vaccine protects nonhuman primates against lethal monkeypox. J. Virol.78(9), 4433–4443 (2004).
   PubMed Web of Science ®Google Scholar
• Fenner F, Henderson DA, Arita I, Jezek Z, Ladnyi ID. Smallpox and its eradication. WHO, Geneva, Switzerland (1988).
   Google Scholar
• Arita I. Smallpox vaccine and its stockpile in 2005. Lancet Infect. Dis.5(10), 647–652 (2005).
   PubMed Web of Science ®Google Scholar
• Government urged to stockpile smallpox vaccine. The Daily Yomiuri, 12 June (2005).
   Google Scholar
• News Medical Net. Canada plans to acquire MVA-based smallpox vaccine (2008).
   Google Scholar
• Cosma A, Nagaraj R, Staib et al. Evaluation of modified vaccinia virus Ankara as an alternative vaccine against smallpox in chronically HIV type 1-infected individuals undergoing HAART. AIDS Res. Hum. Retroviruses23(6), 782–793 (2007).
   PubMed Web of Science ®Google Scholar
• Quenelle DC, Buller RM, Parker S et al. Efficacy of delayed treatment with ST-246 given orally against systemic orthopoxvirus infections in mice. Antimicrob Agents Chemother.51(2), 689–695 (2007).
   PubMed Web of Science ®Google Scholar
• Parker S, Schriewer J, Oberle C et al. Using biomarkers to stage disease progression in a lethal mousepox model treated with CMX001. Antivir. Ther.13(7), 863–873 (2008).
   PubMed Web of Science ®Google Scholar
• Mortimer PP. Can postexposure vaccination against smallpox succeed? Clin. Infect. Dis.36(5), 622–629 (2003).
   PubMed Web of Science ®Google Scholar
• Parker S, Oberle C, Hembrador E et al. Mousepox in the C57BL/6 strain provides a new model for evaluating anti-poxvirus therapies in mammals. Virology385(1), 11–21 (2008).
   PubMed Web of Science ®Google Scholar
• Parker S, Handley L, Buller R. Therapeutic and prophylactic drugs to treat orthopoxvirus infections. Future Virology3(6), 595–612 (2008).
   PubMed Web of Science ®Google Scholar
• Chen N, Li G, Liszewski MK et al. Virulence differences between monkeypoxvirus isolates from West Africa and the Congo basin. Virology340(1), 46–63 (2005).
   PubMed Web of Science ®Google Scholar